Dimitry Nuyten

Technik-/Wissenschafts-/F&E-Leiter bei ARCUS BIOSCIENCES, INC.

Vermögen: 203 569 $ am 30.04.2024

Health Technology

Consumer Services

Aktive Positionen von Dimitry Nuyten

Unternehmen	Position	Beginn	Ende
ARCUS BIOSCIENCES, INC.	Technik-/Wissenschafts-/F&E-Leiter	01.08.2022	-

Unternehmen	Position	Beginn	Ende
NEKTAR THERAPEUTICS	Technik-/Wissenschafts-/F&E-Leiter	19.07.2021	01.04.2022
PFIZER, INC.	Corporate Officer/Principal	01.07.2013	01.03.2019
BRISTOL-MYERS SQUIBB COMPANY	Technik-/Wissenschafts-/F&E-Leiter	01.03.2008	01.06.2013
CHINOOK THERAPEUTICS, INC.	Technik-/Wissenschafts-/F&E-Leiter	22.04.2019	-

University of Groningen	Doctorate Degree
University of Amsterdam	Doctorate Degree

International

Vereinigte Staaten	6
Niederlande	3

Operativ

Chief Tech/Sci/R&D Officer	4
Doctorate Degree	2
Corporate Officer/Principal	1

Sektoral

Health Technology	6
Consumer Services	3

Besetzte Positionen

Aktive

Inaktive

Börsennotierte Unternehmen

Private Unternehmen

Börsennotierte Unternehmen	4
PFIZER, INC.	Health Technology
BRISTOL-MYERS SQUIBB COMPANY	Health Technology
NEKTAR THERAPEUTICS	Health Technology
ARCUS BIOSCIENCES, INC.	Health Technology

Private Unternehmen	1
Aduro BioTech, Inc. Aduro BioTech, Inc. Pharmaceuticals: MajorHealth Technology Aduro BioTech, Inc. is a clinical-stage immunotherapy company, which engages in the discovery, development, and commercialization of therapies that transform the treatment of diseases, including cancer. Its technology platforms include STING Pathway Activator, B-select monoclonal antibody, and LADD, or Live, Attenuated, Double-Deleted Listeria monocytogenes. The company's platforms stimulate and/or regulate innate and adaptive immune responses, either as single agents or in combination with conventional therapies like chemotherapy and radiation as well as other novel immunotherapies. Aduro BioTech was founded in 2000 and is headquartered in Berkeley, CA.	Health Technology

Private Unternehmen

Health Technology